A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 59
- Registration Number
- NCT00072670
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2003-06-26
- Last Posted Date
- 2009-08-28
- Target Recruit Count
- 180
- Registration Number
- NCT00063297
- Locations
- 🇺🇸
Clinical Innovations, Santa Ana, California, United States
🇺🇸University of Mississippi Medical Center-Dept. of Psychiatry, Jackson, Mississippi, United States
🇺🇸Psychiatric Institute of Washington, Washington, DC, District of Columbia, United States
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
Phase 4
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2003-06-05
- Last Posted Date
- 2012-02-07
- Target Recruit Count
- 225
- Registration Number
- NCT00061802
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
- First Posted Date
- 2003-05-19
- Last Posted Date
- 2014-09-08
- Target Recruit Count
- 271
- Registration Number
- NCT00060944
Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media
Phase 3
Completed
- Conditions
- Otitis Media
- First Posted Date
- 2003-01-17
- Last Posted Date
- 2011-01-10
- Target Recruit Count
- 1643
- Registration Number
- NCT00051753
A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast NeoplasmsNeoplasmsNeoplasms by SiteBreast DiseasesSkin Diseases
- Interventions
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2011-04-28
- Target Recruit Count
- 53
- Registration Number
- NCT00050427
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Phase 2
Completed
- Conditions
- Endometrial NeoplasmsUterine NeoplasmsGenital Neoplasms, Female Urogenital Neoplasms
- Interventions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2013-01-08
- Target Recruit Count
- 50
- Registration Number
- NCT00050440
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Endocrine Gland NeoplasmsOvarian DiseasesNeoplasmsAdnexal DiseasesNeoplasms by SiteOvarian NeoplasmsGenital Diseases, Female
- Interventions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2013-01-10
- Target Recruit Count
- 147
- Registration Number
- NCT00050414
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2002-11-28
- Last Posted Date
- 2013-02-01
- Target Recruit Count
- 121
- Registration Number
- NCT00050141
Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2002-11-25
- Last Posted Date
- 2010-04-27
- Target Recruit Count
- 82
- Registration Number
- NCT00050154
© Copyright 2025. All Rights Reserved by MedPath